Theravance Biopharma, Inc.
TBPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $20 | $26 | $15 | $19 |
| % Growth | -23.7% | 70.2% | -17.9% | – |
| Cost of Goods Sold | $8 | $10 | $11 | $0 |
| Gross Profit | $12 | $16 | $4 | $19 |
| % Margin | 59.4% | 60% | 25.6% | 100% |
| R&D Expenses | $8 | $10 | $11 | $9 |
| G&A Expenses | $0 | $0 | $0 | $14 |
| SG&A Expenses | $0 | $0 | $0 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $4 |
| Other Operating Expenses | $10 | $8 | $7 | $0 |
| Operating Expenses | $18 | $18 | $18 | $28 |
| Operating Income | -$6 | -$3 | -$14 | -$9 |
| % Margin | -32.3% | -10.4% | -93.8% | -49.1% |
| Other Income/Exp. Net | $4 | $76 | $0 | $0 |
| Pre-Tax Income | -$3 | $73 | -$14 | -$9 |
| Tax Expense | -$7 | $18 | -$1 | $7 |
| Net Income | $4 | $55 | -$14 | -$16 |
| % Margin | 18.1% | 209.3% | -88.2% | -82.8% |
| EPS | 0.07 | 1.09 | -0.27 | -0.31 |
| % Growth | -93.6% | 503.7% | 12.9% | – |
| EPS Diluted | 0.07 | 1.08 | -0.27 | -0.31 |
| Weighted Avg Shares Out | 51 | 50 | 50 | 49 |
| Weighted Avg Shares Out Dil | 52 | 51 | 50 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$2 | -$2 | -$14 | -$8 |
| % Margin | -9.5% | -8.8% | -91.1% | -40.5% |